Astellas Pharma Common Stock

The latest common stock for ALPMY is $100B as of June 2026. That compares with $100B in the prior-year period — down 0.7% year over year. Investors often review this figure alongside Astellas Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALPMY's common stock moved from $100B to $100B — a 0.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Astellas Pharma's operating scale or balance-sheet position.

A common stock figure of $100B for ALPMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ALPMY's common stock ($100B), review year-over-year change from $100B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Astellas Pharma's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.